Most studies evaluating levels of sLAG3 have found this checkpoint to be elevated in cancer patients compared to healthy donors, with higher levels described in patients with NSCLC [104], hepatocellular carcinoma [51], nasopharyngeal carcinoma [55, 65], differentiated thyroid carcinoma [56], pancreatic ductal adenocarcinoma [174], and basal cell carcinoma [57]. This evidence concerns the gene LAG3 and differentiated thyroid carcinoma.